Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00070954
Other study ID # R21AT000939-01A1
Secondary ID R21AT000939-01A1
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date February 2003
Est. completion date March 2005

Study information

Verified date August 2008
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Electroconvulsive therapy (ECT) is an effective treatment for severe or medication-resistant depression and other psychiatric disorders. A common side effect of ECT is problems with short-term memory during treatment. This study will test whether taking ginkgo biloba (GB) prior to and during the course of ECT will lessen the effects of ECT on short-term memory.


Description:

ECT is a safe and effective modern treatment for severe depression and other psychiatric conditions. An estimated 100,000 treatments occur per year in the United States. ECT's most bothersome adverse effect is memory loss, with all patients receiving ECT experiencing some degree of short-term cognitive impairment. At present there are no known effective pharmacologic treatments to prevent or improve ECT-induced cognitive dysfunction. Preliminary research has shown the herbal preparation GB aids cognitive function and memory in both patients with dementia and in normal volunteers. This study will investigate the utility and safety of GB to minimize the cognitive impairment typically associated with ECT.

Participants in this study will be randomly assigned to receive either twice-daily GB or placebo. Participants will begin taking GB or placebo as soon as consent is obtained and baseline testing is completed in order to reach steady-state plasma levels of GB prior to ECT. Patients will undergo cognitive testing at specified intervals following ECT. The final study visit will occur one week after a participant's final ECT treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 50
Est. completion date March 2005
Est. primary completion date January 2005
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

- DSM-IV diagnosis of major depressive episode, unipolar or bipolar, without psychotic features

- Receiving ECT for depression

- Able to complete detailed neuropsychological testing

Exclusion Criteria

- Psychotic symptoms

- Lifetime history of schizophrenia, schizoaffective disorder, or mental retardation

- Diagnosis of anxiety disorder, obsessive-compulsive disorder, or eating disorder within 1 year of study entry

- Delirium, dementia, or amnestic disorder

- Any active general medical condition or central nervous system disease which could affect cognition or response to treatment

- Diagnosis of active substance abuse or dependence within 6 months of study entry

- ECT within 6 months of study entry

- Known or suspected coagulation disorder

- Anticoagulation or antiplatelet medications, including warfarin, aspirin, clopidogrel, and ticlopidine

- Thiazide diuretics, selective serotonin reuptake inhibitors, trazodone, antipsychotic medications, herbal medications, or other nutritional supplements

- Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ginkgo biloba
EgB 761
Other:
matched placebo
Inactive look-alike placebo

Locations

Country Name City State
United States UMDNJ - NJ Medical School Newark New Jersey

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Center for Complementary and Integrative Health (NCCIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Modified Mini-Mental State Examination 2009
Primary Rey Auditory Verbal Learning Test 2009
Primary Autobiographical Memory Inventory 2003-2009
Primary Spitzer Uniscale of Quality of Life(Uni) 2--3-2009
Primary Health Status Questionnaire 2003-2009
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06460207 - Neurofeedback Removal of Emotional Information From Mind N/A
Completed NCT01365897 - Effectiveness of Modafinil in Improving Cognitive Performance of University Students Phase 4
Recruiting NCT06072378 - The Computational and Neural Mechanisms Linking Decision-making and Memory in Humans N/A
Not yet recruiting NCT02401646 - Clinical Trials for the Effects of Polygoni Multiflori Radix Complex Extract on Memory Improvement Phase 4
Completed NCT01321021 - Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects N/A